Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and care. The joint effort seeks ...

DIMO Healthcare, a leader in the Sri Lankan healthcare sector, has introduced the country’s first Echosens FibroScan® Expert ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

At Boehringer, we're committed to being part of the solution, and the expansion of our partnership with Echosens is one we're particularly excited about. We look forward to working together to ...

PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure-affecting more than 250 ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next ...

DIMO Healthcare has introduced the country’s first Echosens FibroScan Expert 630, revolutionizing non-invasive liver ...